ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)

Zhou, Shipeng; You, Huimin; Qiu, Shuting; Yu, Dawei; Bai, Yan; He, Jincan; Cao, Hua; Che, Qishi; Guo, Jiao*; Su, Zhengquan*广东药学院
Biomedicine and Pharmacotherapy2022-10DOI: 10.1016/j.biopha.2022.113577
16被引8阅读
引用收藏
分享

摘要

Nonalcoholic fatty liver disease (NAFLD) is primarily caused by abnormal lipid metabolism and the accumulation of triglycerides in the liver. NAFLD is also associated with hepatic steatosis and nutritional and energy imbalances and is a chronic liver disease associated with a number of factors. Nuclear receptors play a key role in balancing energy and nutrient metabolism, and the peroxisome proliferator-activated receptor alpha (PPAR alpha) and farnesoid X receptor (FXR) regulate lipid metabolism genes, controlling hepatocyte lipid utilization and regulating bile acid (BA) synthesis and transport. They play an important role in lipid metabolism and BA homeostasis. At present, PPAR alpha and FXR are the most promising targets for the treatment of NAFLD among nuclear receptors. This review focuses on the crosstalk mechanisms and transcriptional regulation of PPAR alpha and FXR in the pathogenesis of NAFLD and summarizes PPAR alpha and FXR drugs in clinical trials, laying a theoretical foundation for the targeted treatment of NAFLD and the development of novel therapeutic strategies.

学科与关键词

关键词
Farnesoid X receptorNonalcoholic fatty liver diseasePeroxisome proliferator-activated receptoralphaTargeted therapy
相关
加载中…
  • The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease
    Li, Yu-Yuan; Cao, Chuang-Yu; Zhou, You-lian; Nie, Yu-Qiang; Cao, Jie; Zhou, Yong-Jian*Arab Journal of Gastroenterology, 2020, 21(3): 162-168.被引 5
  • Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment
    Che, Wensheng; Zhao, Ming; Li, Xiaoqing; Li, Chunlong*; Cho, William C.*; Yu, Shan*Frontiers in Endocrinology, 2022, 13: 1002916.被引 2
  • Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies
    Wang, Guang-Yan; Zhang, Xiao-Yan; Wang, Chun-Jiong; Guan, You-Fei*WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29(1): 75-95.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Biomedicine and Pharmacotherapy
发表日期
2022-10
卷期
第 154 卷
页码
113577
DOI
10.1016/j.biopha.2022.113577
语言
MULTI-LANGUAGE
成果收录
SCIE
资助标注
Science and Technology Program of Guangzhou, China [202103000089]; Guangdong Demonstration Base for Joint Cultivation of Postgraduates (2019); Science Foundation for Distinguished Young Scholars of Guangdong [2020B1515020026]; National Natural Science Foundation of China [21804025]

作者

  • Z

    Zhou, Shipeng (第一作者)

    guangdong pharmaceut univ · new

  • Y

    You, Huimin

    guangdong pharmaceut univ · new

查看全部 10 位作者收起作者
  • Q

    Qiu, Shuting

    guangdong pharmaceut univ · new

  • Y

    Yu, Dawei

    guangdong pharmaceut univ · new

  • B

    Bai, Yan

    guangdong pharmaceut univ

  • H

    He, Jincan

    guangdong pharmaceut univ

  • C

    Cao, Hua

    guangdong pharmaceut univ

  • C

    Che, Qishi

  • G

    Guo, Jiao (通讯)

    guangdong pharmaceut univ

  • S

    Su, Zhengquan (通讯)

    guangdong pharmaceut univ · new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417